Redefining Autoimmunity, Transforming Lives.


Building novel personalized medicines for autoimmune disease with first-of-its-kind targeted drug design and a patient-centered approach


IM Therapeutics is building an HLA-directed platform for new therapies. We have demonstrated early effectiveness in type 1 diabetes and are building a pipeline of targeted therapies across autoimmune diseases.


Our Approach

Our novel therapies are designed to specifically block the action of HLA proteins known to be involved in the trigger of autoimmune response.



October 9, 2019
IM Therapeutics Raises $10 Million Financing Co-Led by JDRF T1D Fund and Morningside Ventures | READ MORE